In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs

Behav Brain Res. 2002 Nov 15;136(2):521-32. doi: 10.1016/s0166-4328(02)00203-6.

Abstract

The rat forced swimming test (FST) distinguishes selective serotonin (5-HT) and selective noradrenaline (NA) reuptake-inhibitors, which respectively increase swimming and climbing behaviours. However, NA-system-mediated inhibition of 5-HT-induced swimming prevents dual 5-HT/NA reuptake-inhibition to produce concurrently climbing with swimming. Since adaptative neurochemical processes occur in the treatment of depression, we examined the influence of long-term antidepressant treatment on these interactions.

Methods: (1) Selective [fluoxetine: 10 mg/kg; desipramine: 10 mg/kg] and non-selective [milnacipran: 40 mg/kg; mirtazapine: 20 mg/kg] antidepressants were administered subacutely (3inj) and chronically (17inj) over 16 days. (2) A subacute fluoxetine-desipramine combination (10-10 mg/kg) was administered in rats that were pre-treated with chronic-desipramine (10 mg/kg per day, 14 days). (3) NA-system-mediated interactions were further examined by combining the alpha(2)-receptor agonist clonidine (5, 10, 20, 200 microg/kg) with 10 mg/kg fluoxetine.

Results: (1) Long-term treatment with either fluoxetine or desipramine does not modify the behavioural response produced by their subacute administration. (2) In contrast, whereas subacute-milnacipran increases climbing solely, chronic-milnacipran produces greater anti-immobility effects and increases both climbing and swimming behaviours. Similarly, the fluoxetine-desipramine combination produces climbing solely, but increases both climbing and swimming behaviours in animals pre-treated with chronic-desipramine. Chronic but not subacute-mirtazapine increases swimming behaviour. (3) clonidine dose-dependently antagonizes fluoxetine-induced anti-immobility effects and swimming behaviour.

Conclusions: Chronic enhancement of NA-transmission alters NA-system-mediated inhibition of 5-HT-induced behaviour in the FST, which may involve alpha(2)-receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Uptake Inhibitors / therapeutic use*
  • Adrenergic alpha-Agonists / pharmacology
  • Animals
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Behavior, Animal / drug effects*
  • Clonidine / pharmacology
  • Cyclopropanes / therapeutic use
  • Depression / drug therapy*
  • Depression / psychology*
  • Desipramine / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Fluoxetine / therapeutic use
  • Male
  • Mianserin / analogs & derivatives*
  • Mianserin / therapeutic use
  • Milnacipran
  • Mirtazapine
  • Motor Activity / drug effects
  • Norepinephrine / physiology*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-2 / drug effects
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Swimming / psychology*

Substances

  • Adrenergic Uptake Inhibitors
  • Adrenergic alpha-Agonists
  • Antidepressive Agents, Second-Generation
  • Cyclopropanes
  • Receptors, Adrenergic, alpha-2
  • Serotonin Uptake Inhibitors
  • Fluoxetine
  • Mianserin
  • Mirtazapine
  • Milnacipran
  • Clonidine
  • Desipramine
  • Norepinephrine